Ophthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus – Nasdaq
Nasdaq |
Ophthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus
Nasdaq Ophthotech CorporationOPHT reported loss of 26 cents per share for the fourth quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 58 cents as well as a loss of $1.86 in the year-ago quarter. With no approved products in its … |
